JP2021528092A5 - - Google Patents
Info
- Publication number
- JP2021528092A5 JP2021528092A5 JP2020573110A JP2020573110A JP2021528092A5 JP 2021528092 A5 JP2021528092 A5 JP 2021528092A5 JP 2020573110 A JP2020573110 A JP 2020573110A JP 2020573110 A JP2020573110 A JP 2020573110A JP 2021528092 A5 JP2021528092 A5 JP 2021528092A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- ali
- antibody
- seq
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025006393A JP7850296B2 (ja) | 2018-07-03 | 2025-01-16 | インフラマソームに関連する疾患又は病態を治療するための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/026,482 | 2018-07-03 | ||
| US16/026,482 US10703811B2 (en) | 2016-12-29 | 2018-07-03 | Methods and compositions for treating multiple sclerosis |
| PCT/US2019/040635 WO2020010273A1 (en) | 2018-07-03 | 2019-07-03 | Compositions and methods for treating inflammasome related diseases or conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025006393A Division JP7850296B2 (ja) | 2018-07-03 | 2025-01-16 | インフラマソームに関連する疾患又は病態を治療するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021528092A JP2021528092A (ja) | 2021-10-21 |
| JP2021528092A5 true JP2021528092A5 (enExample) | 2022-07-08 |
| JP7824030B2 JP7824030B2 (ja) | 2026-03-04 |
Family
ID=78823964
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020573110A Active JP7824030B2 (ja) | 2018-07-03 | 2019-07-03 | インフラマソームに関連する疾患又は病態を治療するための組成物及び方法 |
| JP2025006393A Active JP7850296B2 (ja) | 2018-07-03 | 2025-01-16 | インフラマソームに関連する疾患又は病態を治療するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025006393A Active JP7850296B2 (ja) | 2018-07-03 | 2025-01-16 | インフラマソームに関連する疾患又は病態を治療するための組成物及び方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12570735B2 (enExample) |
| EP (1) | EP3818081A4 (enExample) |
| JP (2) | JP7824030B2 (enExample) |
| KR (1) | KR20210071944A (enExample) |
| CN (1) | CN113316588B (enExample) |
| AU (1) | AU2019297515A1 (enExample) |
| BR (1) | BR112020026798A2 (enExample) |
| CA (1) | CA3105129A1 (enExample) |
| CL (1) | CL2020003447A1 (enExample) |
| CO (1) | CO2021001172A2 (enExample) |
| IL (1) | IL279851A (enExample) |
| MX (1) | MX2021000142A (enExample) |
| PH (1) | PH12020552286A1 (enExample) |
| SG (1) | SG11202013176VA (enExample) |
| WO (1) | WO2020010273A1 (enExample) |
| ZA (2) | ZA202100703B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240060995A1 (en) * | 2012-02-06 | 2024-02-22 | University Of Miami | Innate immune proteins as biomarkers for traumatic brain injury in adult and pediatric patients |
| JP2020503345A (ja) | 2016-12-29 | 2020-01-30 | ユニバーシティ オブ マイアミ | 肺におけるインフラマソーム活性及び炎症をモジュレートする方法 |
| US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
| MX2021000142A (es) | 2018-07-03 | 2021-05-12 | Univ Miami | Composiciones y metodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas. |
| EP4142705A4 (en) * | 2020-04-27 | 2024-07-03 | University of Miami | Compositions and methods for treating inflammasome related diseases or conditions |
| TW202334202A (zh) * | 2021-11-16 | 2023-09-01 | 瑞士商Ａｃ免疫有限公司 | 用於治療和診斷的新分子 |
| JP2025530202A (ja) * | 2022-09-09 | 2025-09-11 | ユニバーシティー オブ マイアミ | 神経疾患を治療するためのインフラマソーム抗体組成物及び方法 |
| WO2024114906A1 (en) * | 2022-11-30 | 2024-06-06 | Mabylon Ag | Antibodies against apoptosis-associated speck-like protein containing a card (asc) and uses thereof |
| WO2026042013A1 (en) * | 2024-08-19 | 2026-02-26 | Institute Of Molecular And Clinical Ophthalmology Basel (Iob) | Mitochondrial therapy |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2763849B1 (fr) | 1997-05-28 | 2000-09-15 | Rhone Poulenc Rorer Sa | Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement des oedemes cerebraux |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| US7244764B2 (en) | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| AU2005243193B2 (en) | 2004-04-29 | 2011-01-27 | Otsuka Pharmaceutical Co., Ltd. | Antibodies specific for glycoprotein VI and methods of producing these antibodies |
| JP4496214B2 (ja) * | 2004-05-17 | 2010-07-07 | 電気化学工業株式会社 | ポリ塩化ビニル繊維及びその製造方法並びに人工毛髪 |
| AU2005306997B2 (en) | 2004-10-25 | 2012-07-05 | Merck Sharp & Dohme Corp. | Anti-ADDL antibodies and uses thereof |
| TW200636064A (en) | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
| CA2623565A1 (en) | 2005-09-28 | 2007-04-05 | Biovascular, Inc. | Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation |
| RS55963B1 (sr) | 2005-12-29 | 2017-09-29 | Janssen Biotech Inc | Humana anti-il-23 antitela, kompozicije, metode i upotrebe |
| EP2447285A3 (en) | 2006-05-25 | 2013-01-16 | Momenta Pharmaceuticals, Inc. | Low molecular weight heparin composition and uses thereof |
| US20100136030A1 (en) * | 2007-02-27 | 2010-06-03 | Lamhamedi-Cherradi Salah-Eddine | Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases |
| US8685400B2 (en) | 2007-07-30 | 2014-04-01 | University Of Miami | Modulating inflammasome activity and inflammation in the central nervous system |
| EP2300000A1 (en) * | 2008-07-03 | 2011-03-30 | University of Massachusetts | Methods and compositions for reducing inflammation and treating inflammatory disorders |
| EP2145624A1 (en) | 2008-07-18 | 2010-01-20 | Sanofi-Aventis | Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment |
| EP2475380A1 (en) | 2009-09-11 | 2012-07-18 | Protaffin Biotechnologie AG | Composition for treatment of cxcl8-mediated lung inflammation |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| SMT202000095T1 (it) | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| IT1406201B1 (it) | 2010-12-10 | 2014-02-14 | Univ Degli Studi Trieste | Biomarcatori per la diagnosi della sclerosi multipla |
| WO2012123299A1 (en) * | 2011-03-11 | 2012-09-20 | Roche Diagnostics Gmbh | Asc as marker for chronic obstructive pulmonary disease (copd) |
| WO2013049278A1 (en) | 2011-09-30 | 2013-04-04 | Novartis Ag | USE OF IL-1 ß BINDING ANTIBODIES |
| CA2863417C (en) | 2012-02-06 | 2020-07-28 | University Of Miami | Innate immune proteins as biomarkers for cns injury |
| TWI480044B (zh) | 2012-03-16 | 2015-04-11 | Taichung Veterans General Hospital | A high molecular weight heparin or low molecular weight heparin for the preparation of a composition for at least two consecutive days of administration to improve the allergic constitution |
| US20140314746A1 (en) * | 2013-03-13 | 2014-10-23 | Philadelphia Health And Education Corporation, d/b/a Drexel University College of Medicine | Methods for treating or preventing fibrosis in subjects afflicted with scleroderma |
| CN105209643A (zh) | 2013-05-17 | 2015-12-30 | 豪夫迈·罗氏有限公司 | 用于诊断和治疗炎性肠病的方法 |
| JP6359013B2 (ja) | 2013-07-29 | 2018-07-18 | 国立大学法人 鹿児島大学 | １，５−ｄ−アンヒドロフルクトースを含むアポトーシス関連スペック様カード蛋白質の機能阻害薬 |
| EP4491180A1 (en) | 2014-01-10 | 2025-01-15 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| EP3183582B1 (en) | 2014-08-18 | 2020-02-12 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Biomarkers for diagnosis and management of neuro-immunological diseases |
| WO2016059571A1 (en) | 2014-10-16 | 2016-04-21 | Novartis Ag | Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis |
| US20160263183A1 (en) | 2015-03-10 | 2016-09-15 | Brown University | Methods for treating lung disease |
| CN114181281A (zh) | 2015-05-12 | 2022-03-15 | 加利福尼亚大学董事会 | 用于炎症和纤维化的肽治疗 |
| CN108349867B (zh) | 2015-08-17 | 2021-03-09 | 安成生物科技股份有限公司 | 用于抑制asc的表达、nlrp3的表达和/或nlrp3炎性复合体的形成的双醋瑞因或其类似物 |
| KR101948048B1 (ko) * | 2016-12-08 | 2019-02-14 | 한양대학교 에리카산학협력단 | 톡소포자충 ｇｒａ７ 항원 유래 재조합 단백질을 유효성분으로 포함하는 결핵 예방 또는 치료용 약학 조성물 |
| JP2020503345A (ja) | 2016-12-29 | 2020-01-30 | ユニバーシティ オブ マイアミ | 肺におけるインフラマソーム活性及び炎症をモジュレートする方法 |
| US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
| US10755739B1 (en) | 2016-12-30 | 2020-08-25 | John Fristrom | Remote railway crossing programmable device and methods thereof |
| AU2018336897A1 (en) | 2017-09-20 | 2020-04-30 | University Of Miami | Method for detecting inflammasome proteins as biomarkers of neurological disorders |
| MX2021000142A (es) | 2018-07-03 | 2021-05-12 | Univ Miami | Composiciones y metodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas. |
-
2019
- 2019-07-03 MX MX2021000142A patent/MX2021000142A/es unknown
- 2019-07-03 KR KR1020217003239A patent/KR20210071944A/ko not_active Ceased
- 2019-07-03 BR BR112020026798-8A patent/BR112020026798A2/pt unknown
- 2019-07-03 JP JP2020573110A patent/JP7824030B2/ja active Active
- 2019-07-03 AU AU2019297515A patent/AU2019297515A1/en active Pending
- 2019-07-03 CA CA3105129A patent/CA3105129A1/en active Pending
- 2019-07-03 CN CN201980056542.1A patent/CN113316588B/zh active Active
- 2019-07-03 US US17/255,653 patent/US12570735B2/en active Active
- 2019-07-03 EP EP19831331.4A patent/EP3818081A4/en active Pending
- 2019-07-03 SG SG11202013176VA patent/SG11202013176VA/en unknown
- 2019-07-03 WO PCT/US2019/040635 patent/WO2020010273A1/en not_active Ceased
-
2020
- 2020-12-29 PH PH12020552286A patent/PH12020552286A1/en unknown
- 2020-12-30 IL IL279851A patent/IL279851A/en unknown
- 2020-12-30 CL CL2020003447A patent/CL2020003447A1/es unknown
-
2021
- 2021-02-01 ZA ZA2021/00703A patent/ZA202100703B/en unknown
- 2021-02-02 CO CONC2021/0001172A patent/CO2021001172A2/es unknown
-
2022
- 2022-01-31 ZA ZA2022/01437A patent/ZA202201437B/en unknown
-
2025
- 2025-01-16 JP JP2025006393A patent/JP7850296B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023515271A5 (enExample) | ||
| JP2021521843A5 (enExample) | ||
| JP2024020298A5 (enExample) | ||
| JP2024109678A5 (enExample) | ||
| JP2023002562A5 (enExample) | ||
| JP2021524256A5 (enExample) | ||
| JP2018535650A5 (enExample) | ||
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| JP2020522281A5 (enExample) | ||
| JP2020522280A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| CA2494008A1 (en) | Anti-myelin associated glycoprotein (mag) antibodies | |
| JP2013542194A5 (enExample) | ||
| JP2006512899A5 (enExample) | ||
| JP2015514110A5 (enExample) | ||
| JP2021527640A5 (enExample) | ||
| JP2016538876A5 (enExample) | ||
| JP2024024114A5 (enExample) | ||
| RU2016122340A (ru) | Il-17a-связующий агент и способы его применения | |
| JP2025067915A5 (enExample) | ||
| JP2023516195A5 (enExample) | ||
| JP2019162119A5 (enExample) | ||
| JP2020513757A5 (enExample) | ||
| JP2020533965A5 (enExample) |